LianBio (LIAN): Price and Financial Metrics
GET POWR RATINGS... FREE!
LIAN Stock Price Chart Interactive Chart >
LIAN Price/Volume Stats
| Current price | $2.91 | 52-week high | $16.37 |
| Prev. close | $3.00 | 52-week low | $2.15 |
| Day low | $2.69 | Volume | 749,100 |
| Day high | $3.06 | Avg. volume | 456,033 |
| 50-day MA | $3.68 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 315.08M |
LianBio (LIAN) Company Bio
Lianbio operates in the healthcare industry focusing on pharmaceutical business. The company is based in Camana Bay, Cayman Islands.
Latest LIAN News From Around the Web
Below are the latest news stories about LianBio that investors may wish to consider to help them evaluate LIAN as an investment opportunity.
LianBio Announces Mavacamten Granted Breakthrough Therapy Designation in ChinaSHANGHAI and PRINCETON, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation in China for mavacamten for the treatment of patients with obstructive hypertrophic cardiomyopathy (oHCM). Breakthrough Therapy Designation |
What Kind Of Investors Own Most Of LianBio (NASDAQ:LIAN)?A look at the shareholders of LianBio ( NASDAQ:LIAN ) can tell us which group is most powerful. Institutions often own... |
LianBio Announces First Patient Dosed in Registrational Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Patients with Obstructive Hypertrophic CardiomyopathyEXPLORER-CN trial designed to support regulatory filing in Mainland ChinaSHANGHAI, China and PRINCETON, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the first patient has been dosed in the Phase 3 EXPLORER-CN clinical trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). “With more than one mil |
LianBio Announces Infigratinib Approved Under Special Named Patient Program for the Treatment of Cholangiocarcinoma in the Pilot Zone of Hainan Province in ChinaSHANGHAI, China and PRINCETON, N.J., Dec. 21, 2021 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that infigratinib has been approved by the Health Commission and Medical Products Administration of Hainan Province, under the special Named Patient Program (NPP), for the treatment of patients with previously treated, unresectable locally advanced or metastatic cholang |
LianBio Provides Corporate Update and Reports Third Quarter 2021 Financial ResultsInitiated and completed dosing in pharmacokinetic (PK) study of mavacamten in healthy Chinese volunteers Initiated Phase 2a clinical trial of infigratinib in Chinese patients with gastric cancer and other advanced solid tumors Strengthened leadership team with appointment of scientific and commercial executives Completed initial public offering for gross proceeds of approximately $334.5 million, providing cash runway through 2023 SHANGHAI, China and PRINCETON, N.J., Dec. 09, 2021 (GLOBE NEWSWIRE |
LIAN Price Returns
| 1-mo | -42.32% |
| 3-mo | -32.64% |
| 6-mo | -81.81% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -52.76% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...